•Patients with cholangiocarcinoma have extremely poor prognoses.
•No molecular targeted agents have been still approved for cholangiocarcinoma treatment.
•RNA sequencing disclosed the fusion transcript EML4-ALK in a patient with cholangiocarcinoma.
•Cholangiocarcinoma share some driver targetable mutations with other solid tumors. READ ARTICLE
European Journal of Internal Medicine DOI:10.1016/j.ejim.2019.10.030
Authors: Domenico Trombetta, Paola Parente, Tiziana Pia Latiano, Federico Pio Fabrizio, Lucia Anna Muscarella
